Adoptive Cell Transfer Therapy in China: Top Tumor-Infiltrating Lymphocytes Companies

BIOOCUS Biotech Ltd. introduces its innovative Adoptive Cell Transfer Therapy with Tumor-Infiltrating Lymphocytes (TIL) for the treatment of cancer. TIL therapy involves extracting T-cells from a patient's tumor, expanding and modifying them in a laboratory, and then re-infusing them back into the patient to target and destroy cancer cells. This personalized immunotherapy approach has shown promising results in treating various types of solid tumors, including melanoma, cervical cancer, and gastrointestinal malignancies, BIOOCUS Biotech is dedicated to advancing cancer treatment through cutting-edge research and development. Our TIL therapy is designed to harness the body's own immune system to fight cancer, offering a potential alternative to traditional treatments like chemotherapy and radiation therapy. By leveraging the power of T-cells, our therapy aims to provide patients with a targeted and effective treatment option, while minimizing the side effects associated with conventional cancer therapies